Highest-materiality recent filing
Telomir-Zn dose-dependently improved survival, reduced hepatic copper burden and liver injury biomarkers (ALT, AST, bilirubin) in zebrafish Wilson's disease model.
FDA cleared IND for lead candidate Telomir-Zn in advanced/metastatic triple-negative breast cancer.
Telomir Pharmaceuticals completes acquisition of TELI, consolidating global rights to Telomir-1
Acquired 100% of TELI for 34,389,710 restricted shares of Telomir common stock to former TELI shareholders.
Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in metastatic triple-negative breast cancer
IND submitted March 31, 2026 for oral Telomir-Zn (Telomir-1) in advanced/metastatic TNBC.
TELO shareholders approve acquisition of Teli Pharma and increase share reserve to 11.5M
Acquisition of Teli Pharmaceuticals approved; issuance of >20% new shares authorized.
Near-complete tumor cell mortality in MDA-MB-468 (Basal-A/EGFR-high) TNBC cells at 72h.
Received Nasdaq notice on Jan 8, 2026 for failure to hold annual meeting within 12 months of fiscal year end (Rule 5620(a)).
Telomir-1 reduces tumor growth and metastases in aggressive TNBC models in preclinical study
Telomir-1 showed statistically significant reductions in primary tumor growth in two of three aggressive TNBC zebrafish xenograft models.
No treatment-related adverse or dose-limiting toxicities observed across cardiovascular, respiratory, phototoxicity, and repeat-dose safety studies in rats and dogs.
Telomir Pharma reports Telomir-1 reduces PSA in prostate cancer cells in dose-related manner
Telomir-1 reduced PSA levels in dose-related manner in androgen-responsive human prostate cancer cells (LNCaP) in vitro.
Telomir-1 produced dose-dependent reduction in viability of human HL60 leukemia cells (aggressive AML model).
Telomir-1 outperforms FDA-approved DFO in reducing intracellular iron in preclinical study
Telomir-1 reduced intracellular Fe²⁺ in human keratinocytes in dose- and time-dependent manner at low-micromolar concentrations.
Telomir signs binding LOI to acquire TELI, consolidating worldwide rights to Telomir-1
Acquires all TELI shares via stock-for-stock exchange; exchange ratio based on third-party valuation.
Telomir Pharma reports Telomir-1 kills pancreatic cancer cells in vitro; plans further studies
Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in concentration-dependent manner.
Telomir-1 selectively kills triple-negative breast cancer cells in lab studies
Telomir-1 produced concentration-dependent reduction in TNBC cell survival; iron addition reversed effect, confirming iron-dependent mechanism.
Telomir-1 restores MASPIN and RASSF1A tumor suppressors in prostate cancer models
Telomir-1 reversed DNA hypermethylation to reactivate MASPIN and RASSF1A in aggressive prostate cancer models.
Telomir reports preclinical data: Telomir-1 reactivates CDKN2A, beats rapamycin and chemo
New data in PC3 human prostate cancer xenografts shows Telomir-1 inhibits DNA hypermethylation of CDKN2A.
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes
Telomir-1 inhibited JMJD3, FBXL10, and FBXL11 histone demethylase enzymes in a Eurofins Discovery study.
Telomir-1 increased mitochondrial energy (WST-1 assay) and reduced ROS under basal and stress conditions.
Telomir Pharmaceuticals sells 1.1M shares in block sales, raises ~$2.9M
Sold 1,100,000 shares at avg price $2.6045 (premium to prior close) to institutional investors.
In PC3 xenograft model, Telomir-1 fully reversed STAT1 hypermethylation after 21-day oral daily dosing.
Telomir Pharmaceuticals announces positive preclinical data for Telomir-1 in progeria cell lines
Telomir-1 significantly increased cell viability in human HGPS cells under basal and metal-toxic conditions.
Telomir-1 shows dose-dependent reversal of Wilson's disease symptoms in animal model
Up to 4-5x reduction in episodic tremor events; normalization of swim and exploratory behavior.
Telomir-1 preclinical study in Werner Syndrome model shows 100% survival, reverses epigenetic aging
Oral Telomir-1 restored healthy DNA methylation at two CpG island regions, resetting the epigenetic clock.
Telomir Pharmaceuticals announces BIO 2025 participation and preclinical progress for Telomir-1
Telomir will participate in the BIO International Convention 2025 in Boston from June 16-19, 2025, with scheduled partnering meetings.
Telomir Pharmaceuticals raises $3M via premium equity sale from largest shareholder
$3 million raised via direct investment by Bayshore Trust (largest shareholder) at $3.00/share, 18% premium to $2.54 close.
New preclinical data show Telomir-1 improved cell viability under stress and boosted mitochondrial function in human cell lines.
Telomir-1 reduces tumor size ~50% in prostate cancer model; protects against chemo toxicity
Telomir-1 alone (low and high doses) reduced tumor growth ~50% in aggressive human prostate cancer animal model.
Telomir announces Telomir-1 reverses calcium dysregulation in human cell lines
Telomir-1 fully reversed calcium dysregulation in human keratinocyte (HaCaT) and retinal (ARPE-19) cell lines under oxidative stress.
Telomir-1 reduces oxidative stress in human retinal cells, advancing potential AMD treatment
Telomir-1 significantly reduced reactive oxygen species (ROS) elevation from copper and iron exposure in human retinal cell lines.
Telomir-1 restores lifespan to near-normal in preclinical progeria model
In C. elegans with wrn-1 mutation (Werner Syndrome model), Telomir-1 restored lifespan to near-normal levels.
Telomir-1 shows copper-binding ability; Wilson's disease program advanced
Preclinical studies show Telomir-1 strongly binds copper, targeting Wilson's disease caused by copper accumulation.
Telomir-1 reverses insulin resistance to near pre-diabetes in zebrafish T2D study
Telomir-1 restored glucose homeostasis, reducing HOMA-IR values and improving oral glucose tolerance in zebrafish model.
On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026
Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the "Company"). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of Telomir Pharmaceuticals, Inc. (the “Company”), effective on that date.
On May 15, 2025, the Company entered into an Employment Agreement (the “Employment Agreement”) with Mr. Weichselbaum to serve as chief financial officer of the Company beginning on May 19, 2025 (the “Start Date”).
On November 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) received written notice of resignation from Michael Jerman resigning, with immediate effect, from his positions a member of the Board of Directors of the Company (the “ Board ”) and as Chair of the Audit Committee
On June 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) and Nathen Fuentes entered into a Confidential Separation and Mutual General Release Agreement (the “ Separation Agreement ”) whereby both the Company and Mr. Fuentes mutually agreed that Mr. Fuentes’ employment as a Chief Financial Officer of the Company would end as of June 18, 2024.
On June 18, 2024, the Board of the Company appointed Michelle Yanez, MBA as the Chief Financial Officer, of the Company.
On April 10, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) received written notice of resignation from Christos Nicholoudis, Esq. resigning, with immediate effect, from his positions as the General Counsel and a member of the Board of Directors of the Company.
On April 10, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) received written notice of resignation from Christos Nicholoudis, Esq. resigning, with immediate effect, from his positions as the General Counsel and a member of the Board of Directors of the Company.
Max materiality 0.95 · Median 0.60 · Most common event other_material